| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | 0.22 | 4e-05 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.47 | 5e-05 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.12 | 5e-05 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.22 | 7e-05 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.13 | 7e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.13 | 7e-05 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 9e-05 |